Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Zoonotic and vector-borne emerging tropical diseases pose a constant threat

A recent article published in the journal Frontiers in Tropical Diseases assessed the threat of emerging zoonotic and vector-borne tropical diseases.

26 May 2021

Previous H3N2 influenza A infection may explain some cases of severe COVID-19

According to research from the University of California, some cases of severe coronavirus disease 2019 (COVID-19) may be related to the immunological memory of previous H3N2 influenza A infection.

26 May 2021

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

A new study aims to identify antibody-based biomarkers associated with the humoral immune response that could be a standard CoP candidate for COVID-19. Further, standardization of research methods to measure these biomarkers has also been conducted.

25 May 2021

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

A team of international scientists recently conducted a randomized clinical trial to assess the safety and efficacy profiles of a novel probiotic formulation in symptomatic coronavirus disease 2019 (COVID-19) patients. The findings indicate that the probiotic formulation is highly effective in reducing symptom severity in COVID-19 patients without causing any adverse events.

25 May 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Since COVID-19 was first detected in December 2019 in Wuhan, China, many different variants of its causative virus – SARS-CoV-2 – have emerged. Through increased viral fitness, some of these have risen to predominance over earlier variants in a remarkably short period of time. New research, by a team of scientists at major institutions in France, examines the reasons behind this phenomenon in one such variant of concern (VOC), the so-called UK variant.

25 May 2021

Could 6′,6′-difluoro-aristeromycin (DFA) have broad-spectrum antiviral potential against coronaviruses?

Researchers at the Leiden University Medical Center demonstrated that low-micromolar concentrations of 6′,6′-difluoro24 aristeromycin (DFA), an adenosine nucleoside analog, strongly inhibits the replication of Middle East respiratory syndrome coronavirus (MERS-CoV) in a cell-based infection assay.

25 May 2021

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

The aim of this study investigates the impact of different types of vaccines on the anti-SARS-CoV-2 Immunoglobulin A (IgA) and Immunoglobulin G (IgG) antibody levels found in human milk.

25 May 2021

Heterologous prime-boost immunization with AstraZeneca and Pfizer COVID-19 vaccines safe and well-tolerated, study finds

A team of scientists from Germany has recently evaluated the reactogenicity profile of heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination among healthcare workers. The findings reveal that a 12-week interval regimen of heterologous vaccination is well-tolerated among participants. The study is currently available on the medRxiv* preprint server.

25 May 2021

Researchers explore strategies that could help the homeless during pandemics

A team of UBC Okanagan researchers is looking at strategies that could help the homeless during a pandemic.

25 May 2021

DEFINE: Trial designed to test repurposed treatments in patients with COVID-19

A team of scientists from the United Kingdom has designed an experimental medicine trial to evaluate the safety/tolerability, and efficacy profiles of a panel of candidate repurposed therapies in coronavirus disease 2019 (COVID-19) patients. A detailed outline of the trial is currently available on the medRxiv* preprint server.

25 May 2021

Research looks at viral presence around hospitalized COVID-19 patients

Researchers in Canada aimed to determine the burden of SARS-CoV-2 in the air and on surfaces in the rooms of patients hospitalized with COVID-19.

25 May 2021

Discovery of novel SARS-related coronaviruses in bats

In a recent study published on the bioRxiv* server, Peng Zhou, Zheng-Li Shi and colleagues at the Wuhan Institute of Virology, with collaboration from scientists at the University of Chinese Academy of Sciences in China, have identified a new lineage of SARS-related coronaviruses that utilize bat angiotensin-converting enzyme 2 (ACE2) receptors for cell entry, which is the same receptor used by SARS-CoV-2 to infect host cells.

25 May 2021

Do mixed COVID-19 vaccines provide immunity?

The initial results of the CombivacS trial found that the antibody levels in individuals increased by 150 times when the Pfizer messenger ribonucleic acid (mRNA) vaccine was given after a first dose of the AstraZeneca severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, with only mild common side effects.

24 May 2021

Why COVID-19 patients have more pathogenic bacteria in their noses

Researchers compared the nasal microbiome of coronavirus disease 2019 (COVID-19) patients, healthy individuals, and healthcare workers. These studies indicated an increase in the pathogen Pseudomonas aeruginosa present in the nasal microbiome of COVID-19 patients, which may be responsible for other secondary infections.

24 May 2021

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Antibodies, Antibody, Assay, Coronavirus, Efficacy, Healthcare, Pandemic, Protein, Receptor, Research, Vaccine, Virus, Coronavirus Disease COVID-19,

24 May 2021

Could an antiviral mouthwash using silver nanoparticles prevent COVID-19?

In a recent study by researchers in Mexico, Russia and Spain, silver nanoparticles (AgNPs) were found to inhibit SARS-CoV-2 in healthcare workers. They propose a non-pharmaceutical public health intervention consisting of mouthwash and nose rinse with an AgNPs solution to reduce morbidity among healthcare personnel exposed to the SARS-CoV-2 virus.

24 May 2021

Little evidence for mRNA COVID-19 vaccine-associated thrombocytopenia, suggests new FDA study

Even as a host of vaccines have been rolled out to counter the coronavirus disease 2019 (COVID-19) pandemic, some serious adverse effects have been reported, in the form of thrombocytopenia. A new study in the journal Vaccine reports the results of an evaluation of reported cases of this condition, using data from the Vaccine Adverse Event Reporting System (VAERS).

24 May 2021

Novel natural compounds may help treat COVID-19, study suggests

A new study in the journal Chemistry Europe reports two natural compounds identified by virtual screening and computational modeling as having great promise for the development of drugs against SARS-CoV-2.

24 May 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Zoonotic and vector-borne emerging tropical diseases pose a constant threat

Previous H3N2 influenza A infection may explain some cases of severe COVID-19

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Could 6′,6′-difluoro-aristeromycin (DFA) have broad-spectrum antiviral potential against coronaviruses?

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

Heterologous prime-boost immunization with AstraZeneca and Pfizer COVID-19 vaccines safe and well-tolerated, study finds

Researchers explore strategies that could help the homeless during pandemics

DEFINE: Trial designed to test repurposed treatments in patients with COVID-19

Research looks at viral presence around hospitalized COVID-19 patients

Discovery of novel SARS-related coronaviruses in bats

Do mixed COVID-19 vaccines provide immunity?

Why COVID-19 patients have more pathogenic bacteria in their noses

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Could an antiviral mouthwash using silver nanoparticles prevent COVID-19?

Little evidence for mRNA COVID-19 vaccine-associated thrombocytopenia, suggests new FDA study

Novel natural compounds may help treat COVID-19, study suggests

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in